Our data showed that silencing BYSL caused cell cycle arrest at G1 phase in glioma cells, which was further verified by the downregulation of cyclin D1 and CDKs (CDK4 and CDK6) and the upregulation of CDKIs (P21 and P27). Here, CDK6 is linked to central nervous system cancer.